Bill Ackman Eyes New Fund to Bet Against Market Complacency 
SanDisk Joins Nasdaq-100, Replacing Atlassian on April 20 
Rio Tinto's California Boron Assets Attract Over a Dozen Bidders, Valued at Up to $2 Billion 
Abbott Laboratories Ordered to Pay $53 Million in Premature Infant Formula Lawsuit 
China Vanke Seeks Bond Extension Amid Mounting Debt Crisis 
TSMC Posts Strong Q1 2025 Revenue, Riding AI Chip Demand Wave 
FedEx Pilots and Union Reach Tentative Agreement on 40% Pay Increase 
NIO ES9 SUV Launch Sends HK Shares Down 7% Despite Bold Pricing Strategy 
Alibaba Shares Slide as Jefferies Slashes Price Target Over AI Spending and Business Losses 
BHP's Incoming CEO Visits China Amid Pricing Dispute with CMRG 
China's AI Stocks Surge as Zhipu and MiniMax Hit Record Highs 
U.S. Automakers Push Back Against EU Rules Blocking American Trucks from European Market 
Bendigo and Adelaide Bank Posts Strong Q3 Earnings, Announces AI-Driven Job Cuts 
Chinese Brands Are Taking Over Brazil — And It's Just Getting Started 
Chalco Stock Surges as Q1 2025 Profit Forecast Jumps Up to 58% 
San Francisco Suspect Arrested After Molotov Cocktail Attack on OpenAI CEO Sam Altman's Home 
Goldman Sachs, ANZ Cut Oil Forecasts Amid U.S.-Iran Ceasefire Hopes 
ROCKVILLE, Md., Nov. 02, 2016 -- REGENXBIO Inc. (Nasdaq:RGNX), a leading biotechnology company focused on the development, commercialization and licensing of recombinant adeno-associated virus (AAV) gene therapy based on its proprietary NAV® Technology Platform, today announced that it will host a conference call on Wednesday, November 9, 2016 at 4:30 p.m. ET to discuss its financial results for the quarter ended September 30, 2016 and recent operational highlights.
To access the live call by phone, dial (844) 287-6621 (domestic) or (530) 379-4558 (international), and enter the passcode 7457282. To access a live or recorded webcast of the call, please visit the “Investors” section of the REGENXBIO website at www.regenxbio.com. The recorded webcast will be available for approximately 30 days following the call.
About REGENXBIO
REGENXBIO is a leading biotechnology company focused on the development, commercialization and licensing of recombinant adeno-associated virus (AAV) gene therapy. REGENXBIO's NAV® Technology Platform, a proprietary AAV gene delivery platform, consists of exclusive rights to more than 100 novel AAV vectors, including AAV7, AAV8, AAV9 and AAVrh10. REGENXBIO's mission is to transform the lives of patients suffering from severe diseases with significant unmet medical need by developing and commercializing in vivo gene therapy products based on REGENXBIO's NAV Technology Platform. REGENXBIO seeks to accomplish this mission through a combination of internal development efforts and third-party NAV Technology Platform licensees. As of June 30, 2016, REGENXBIO's NAV Technology Platform was being applied in the development of 29 product candidates for a variety of diseases, including five internally developed candidates and 24 partnered candidates developed by REGENXBIO's licensees.
CONTACT: Investors Heather Savelle, 646-395-3734 [email protected] Media Laura Bagby, 312-448-8098 [email protected]
